HMOX1 and neoplasm: When analyzing the transcriptional profile of the TME post treatment it was apparent that most of the transcriptional changes observed in the TME in the acute phase of tumor regression (36 h post initiation of treatment) were driven by KCL-HO-1i (419 upregulated DEGs) compared to chemotherapy (common to both gemcitabine and 5-FU; 30 common upregulated DEGs) across treatment cohorts.